Allosteric protein protein interaction modulator - Iambic Therapeutics
Alternative Names: Allosteric PPI modulator - Iambic Therapeutics; Effector protein for solid tumors - Iambic TherapeuticsLatest Information Update: 29 Apr 2024
At a glance
- Originator Iambic Therapeutics
- Class Antineoplastics
- Mechanism of Action Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 29 Mar 2024 Allosteric protein protein interactions modulators - Iambic Therapeutics is available for licensing as of 29 Mar 2024. https://www.iambic.ai/partnerships
- 29 Mar 2024 Early research in Solid tumours in USA (unspecified route) (Iambic Therapeutics pipeline, March 2024)